Australia's AdAlta surges as partner lands up to $120 million cell therapy deal
BUZZ-Australia's AdAlta surges as partner lands up to $120 million cell therapy deal ** Shares of AdAlta 1AD.AX rise as much as 33.3% to A$0.0040, marking their biggest intraday pct gain since September 3
** Shares hit their highest level since September 4
** Biotech firm says its cell therapy manufacturing partner Oribiotech has signed a 10-year agreement worth up to US$120 million
** Adds, deal will integrate Oribiotech's IRO automated manufacturing platform for cell therapies into production of an approved and commercialised cell therapy
** 1AD up 16.7% so far this week, its strongest weekly move since August 17
** Nearly 14 million shares change hands, about 7.8x the 30-day average
** YTD, stock up 16.7%, including session's moves
(Reporting by Subhalakshmi Dey in Bengaluru)
Recent news on Adalta
See all newsAustralia's AdAlta rises on FDA granting orphan drug status to lead cancer therapy
Brief: Adalta Says FDA Assigns Orphan Drug Designation For EW-001 In Mesothelioma To Adalta
Australia's AdAlta surges as partner lands up to $120 million cell therapy deal
Brief: Adalta Says Oribiotech Deal Validates Adalta Manufacturing Strategy
Brief: Adalta Says Regulatory Advisors Appointed For BZDS1901